Rapid Micro Biosystems (RPID) Competitors

$1.23 +0.03 (+2.50%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$1.23 0.00 (-0.41%)

As of 09/11/2026 04:10 PM Eastern

RPID vs. QSI, CDXS, MXCT, QTRX, and NAUT

Should you buy Rapid Micro Biosystems stock or one of its competitors? Rapid Micro Biosystems's main competitors and comparable companies include Quantum-Si (QSI), Codexis (CDXS), MaxCyte (MXCT), Quanterix (QTRX), and Nautilus Biotechnology (NAUT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Rapid Micro Biosystems compare to Quantum-Si?

Rapid Micro Biosystems (NASDAQ:RPID) and Quantum-Si (NASDAQ:QSI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

52.6% of Rapid Micro Biosystems shares are held by institutional investors. Comparatively, 39.9% of Quantum-Si shares are held by institutional investors. 12.7% of Rapid Micro Biosystems shares are held by insiders. Comparatively, 22.0% of Quantum-Si shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Rapid Micro Biosystems has a net margin of -145.56% compared to Quantum-Si's net margin of -6,138.26%. Quantum-Si's return on equity of -47.12% beat Rapid Micro Biosystems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rapid Micro Biosystems	-145.56%	-177.04%	-73.12%
Quantum-Si	-6,138.26%	-47.12%	-43.18%

Rapid Micro Biosystems has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market. Comparatively, Quantum-Si has a beta of 3.25, suggesting that its share price is 225% more volatile than the broader market.

Rapid Micro Biosystems currently has a consensus target price of $6.00, suggesting a potential upside of 387.80%. Quantum-Si has a consensus target price of $1.00, suggesting a potential upside of 35.14%. Given Rapid Micro Biosystems' stronger consensus rating and higher probable upside, equities analysts plainly believe Rapid Micro Biosystems is more favorable than Quantum-Si.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapid Micro Biosystems	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Quantum-Si	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Rapid Micro Biosystems has higher revenue and earnings than Quantum-Si. Quantum-Si is trading at a lower price-to-earnings ratio than Rapid Micro Biosystems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapid Micro Biosystems	$33.59M	1.84	-$47.12M	-$1.12	N/A
Quantum-Si	$2.44M	66.38	-$101.34M	-$0.46	N/A

In the previous week, Quantum-Si had 5 more articles in the media than Rapid Micro Biosystems. MarketBeat recorded 6 mentions for Quantum-Si and 1 mentions for Rapid Micro Biosystems. Rapid Micro Biosystems' average media sentiment score of 1.87 beat Quantum-Si's score of 0.52 indicating that Rapid Micro Biosystems is being referred to more favorably in the media.

Company	Overall Sentiment
Rapid Micro Biosystems	Very Positive
Quantum-Si	Positive

Summary

Rapid Micro Biosystems beats Quantum-Si on 9 of the 16 factors compared between the two stocks.

How does Rapid Micro Biosystems compare to Codexis?

Codexis (NASDAQ:CDXS) and Rapid Micro Biosystems (NASDAQ:RPID) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

Codexis currently has a consensus price target of $6.50, indicating a potential upside of 343.69%. Rapid Micro Biosystems has a consensus price target of $6.00, indicating a potential upside of 387.80%. Given Rapid Micro Biosystems' stronger consensus rating and higher probable upside, analysts clearly believe Rapid Micro Biosystems is more favorable than Codexis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Rapid Micro Biosystems	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Codexis and Codexis both had 1 articles in the media. Codexis' average media sentiment score of 1.87 equaled Rapid Micro Biosystems'average media sentiment score.

Company	Overall Sentiment
Codexis	Very Positive
Rapid Micro Biosystems	Very Positive

78.5% of Codexis shares are owned by institutional investors. Comparatively, 52.6% of Rapid Micro Biosystems shares are owned by institutional investors. 3.5% of Codexis shares are owned by insiders. Comparatively, 12.7% of Rapid Micro Biosystems shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Codexis has higher revenue and earnings than Rapid Micro Biosystems. Codexis is trading at a lower price-to-earnings ratio than Rapid Micro Biosystems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$70.39M	2.28	-$43.97M	-$0.34	N/A
Rapid Micro Biosystems	$33.59M	1.84	-$47.12M	-$1.12	N/A

Codexis has a beta of 2.52, suggesting that its stock price is 152% more volatile than the broader market. Comparatively, Rapid Micro Biosystems has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market.

Codexis has a net margin of -39.55% compared to Rapid Micro Biosystems' net margin of -145.56%. Codexis' return on equity of -74.36% beat Rapid Micro Biosystems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-39.55%	-74.36%	-23.58%
Rapid Micro Biosystems	-145.56%	-177.04%	-73.12%

Summary

Codexis beats Rapid Micro Biosystems on 9 of the 13 factors compared between the two stocks.

How does Rapid Micro Biosystems compare to MaxCyte?

MaxCyte (NASDAQ:MXCT) and Rapid Micro Biosystems (NASDAQ:RPID) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

MaxCyte has higher earnings, but lower revenue than Rapid Micro Biosystems. MaxCyte is trading at a lower price-to-earnings ratio than Rapid Micro Biosystems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MaxCyte	$33.03M	3.62	-$44.63M	-$0.33	N/A
Rapid Micro Biosystems	$33.59M	1.84	-$47.12M	-$1.12	N/A

68.8% of MaxCyte shares are held by institutional investors. Comparatively, 52.6% of Rapid Micro Biosystems shares are held by institutional investors. 4.1% of MaxCyte shares are held by company insiders. Comparatively, 12.7% of Rapid Micro Biosystems shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

MaxCyte has a net margin of -114.77% compared to Rapid Micro Biosystems' net margin of -145.56%. MaxCyte's return on equity of -18.92% beat Rapid Micro Biosystems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MaxCyte	-114.77%	-18.92%	-16.14%
Rapid Micro Biosystems	-145.56%	-177.04%	-73.12%

In the previous week, MaxCyte had 1 more articles in the media than Rapid Micro Biosystems. MarketBeat recorded 2 mentions for MaxCyte and 1 mentions for Rapid Micro Biosystems. Rapid Micro Biosystems' average media sentiment score of 1.87 beat MaxCyte's score of 0.90 indicating that Rapid Micro Biosystems is being referred to more favorably in the news media.

Company	Overall Sentiment
MaxCyte	Positive
Rapid Micro Biosystems	Very Positive

MaxCyte has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market. Comparatively, Rapid Micro Biosystems has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market.

MaxCyte presently has a consensus target price of $5.00, suggesting a potential upside of 331.03%. Rapid Micro Biosystems has a consensus target price of $6.00, suggesting a potential upside of 387.80%. Given Rapid Micro Biosystems' stronger consensus rating and higher probable upside, analysts plainly believe Rapid Micro Biosystems is more favorable than MaxCyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MaxCyte	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rapid Micro Biosystems	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

MaxCyte beats Rapid Micro Biosystems on 9 of the 16 factors compared between the two stocks.

How does Rapid Micro Biosystems compare to Quanterix?

Rapid Micro Biosystems (NASDAQ:RPID) and Quanterix (NASDAQ:QTRX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

Quanterix has a net margin of -80.25% compared to Rapid Micro Biosystems' net margin of -145.56%. Quanterix's return on equity of -26.09% beat Rapid Micro Biosystems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rapid Micro Biosystems	-145.56%	-177.04%	-73.12%
Quanterix	-80.25%	-26.09%	-19.03%

Rapid Micro Biosystems has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market. Comparatively, Quanterix has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market.

In the previous week, Rapid Micro Biosystems and Rapid Micro Biosystems both had 1 articles in the media. Rapid Micro Biosystems' average media sentiment score of 1.87 equaled Quanterix'saverage media sentiment score.

Company	Overall Sentiment
Rapid Micro Biosystems	Very Positive
Quanterix	Very Positive

52.6% of Rapid Micro Biosystems shares are owned by institutional investors. Comparatively, 86.5% of Quanterix shares are owned by institutional investors. 12.7% of Rapid Micro Biosystems shares are owned by company insiders. Comparatively, 1.5% of Quanterix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Rapid Micro Biosystems presently has a consensus price target of $6.00, suggesting a potential upside of 387.80%. Quanterix has a consensus price target of $3.00, suggesting a potential upside of 17.19%. Given Rapid Micro Biosystems' stronger consensus rating and higher possible upside, equities analysts plainly believe Rapid Micro Biosystems is more favorable than Quanterix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapid Micro Biosystems	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Rapid Micro Biosystems has higher earnings, but lower revenue than Quanterix. Rapid Micro Biosystems is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapid Micro Biosystems	$33.59M	1.84	-$47.12M	-$1.12	N/A
Quanterix	$138.90M	0.87	-$107.15M	-$2.63	N/A

Summary

Rapid Micro Biosystems beats Quanterix on 8 of the 14 factors compared between the two stocks.

How does Rapid Micro Biosystems compare to Nautilus Biotechnology?

Nautilus Biotechnology (NASDAQ:NAUT) and Rapid Micro Biosystems (NASDAQ:RPID) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Nautilus Biotechnology has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market. Comparatively, Rapid Micro Biosystems has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market.

Rapid Micro Biosystems has higher revenue and earnings than Nautilus Biotechnology. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Rapid Micro Biosystems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.45	N/A
Rapid Micro Biosystems	$33.59M	1.84	-$47.12M	-$1.12	N/A

Nautilus Biotechnology has a net margin of 0.00% compared to Rapid Micro Biosystems' net margin of -145.56%. Nautilus Biotechnology's return on equity of -37.58% beat Rapid Micro Biosystems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nautilus Biotechnology	N/A	-37.58%	-30.83%
Rapid Micro Biosystems	-145.56%	-177.04%	-73.12%

In the previous week, Nautilus Biotechnology had 4 more articles in the media than Rapid Micro Biosystems. MarketBeat recorded 5 mentions for Nautilus Biotechnology and 1 mentions for Rapid Micro Biosystems. Rapid Micro Biosystems' average media sentiment score of 1.87 beat Nautilus Biotechnology's score of 0.74 indicating that Rapid Micro Biosystems is being referred to more favorably in the news media.

Company	Overall Sentiment
Nautilus Biotechnology	Positive
Rapid Micro Biosystems	Very Positive

50.7% of Nautilus Biotechnology shares are owned by institutional investors. Comparatively, 52.6% of Rapid Micro Biosystems shares are owned by institutional investors. 41.1% of Nautilus Biotechnology shares are owned by insiders. Comparatively, 12.7% of Rapid Micro Biosystems shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Nautilus Biotechnology presently has a consensus price target of $4.00, indicating a potential upside of 292.16%. Rapid Micro Biosystems has a consensus price target of $6.00, indicating a potential upside of 387.80%. Given Rapid Micro Biosystems' higher probable upside, analysts plainly believe Rapid Micro Biosystems is more favorable than Nautilus Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Rapid Micro Biosystems	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Rapid Micro Biosystems beats Nautilus Biotechnology on 7 of the 13 factors compared between the two stocks.

Get Rapid Micro Biosystems News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RPID and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RPID vs. The Competition

Export

Metric	Rapid Micro Biosystems	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$61.70M	$9.74B	$7.16B	$12.85B
Dividend Yield	N/A	1.48%	2.57%	11.72%
P/E Ratio	-1.10	66.42	274.94	25.36
Price / Sales	1.84	108.69	685.43	116.41
Price / Cash	N/A	26.35	76.65	51.52
Price / Book	1.64	5.28	10.33	6.20
Net Income	-$47.12M	$56.67B	$3.50B	$358.50M
7 Day Performance	-6.11%	-2.15%	-3.32%	-2.35%
1 Month Performance	-27.65%	-1.93%	-0.53%	-3.23%
1 Year Performance	-59.41%	25.04%	23.51%	8.79%

Rapid Micro Biosystems Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RPID Rapid Micro Biosystems	2.3591 of 5 stars	$1.23 +2.5%	$6.00 +387.8%	-59.4%	$61.70M	$33.59M	N/A	200	Positive News
QSI Quantum-Si	2.6337 of 5 stars	$0.76 -0.8%	$1.00 +31.6%	-37.3%	$167.66M	$2.44M	N/A	150	News Coverage Analyst Downgrade
CDXS Codexis	3.1035 of 5 stars	$1.43 -2.1%	$6.50 +354.5%	-39.7%	$159.88M	$77.68M	N/A	250
MXCT MaxCyte	2.819 of 5 stars	$1.28 -0.4%	$5.00 +292.2%	-20.0%	$132.10M	$33.03M	N/A	80	Positive News Analyst Downgrade Gap Down
QTRX Quanterix	1.738 of 5 stars	$2.73 +1.5%	$3.00 +9.9%	-46.8%	$127.22M	$138.90M	N/A	460

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RPID) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rapid Micro Biosystems (RPID) Competitors

RPID vs. QSI, CDXS, MXCT, QTRX, and NAUT

How does Rapid Micro Biosystems compare to Quantum-Si?

Summary

How does Rapid Micro Biosystems compare to Codexis?

Summary

How does Rapid Micro Biosystems compare to MaxCyte?

Summary

How does Rapid Micro Biosystems compare to Quanterix?

Summary

How does Rapid Micro Biosystems compare to Nautilus Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RPID vs. The Competition

Rapid Micro Biosystems Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rapid Micro Biosystems (RPID) Competitors

RPID vs. QSI, CDXS, MXCT, QTRX, and NAUT

How does Rapid Micro Biosystems compare to Quantum-Si?

Do insiders & institutionals hold more shares of RPID or QSI?

Is RPID or QSI more profitable?

Which has more volatility & risk, RPID or QSI?

Do analysts rate RPID or QSI?

Which has better earnings and valuation, RPID or QSI?

Does the media refer more to RPID or QSI?

Summary

How does Rapid Micro Biosystems compare to Codexis?

Do analysts prefer CDXS or RPID?

Does the media prefer CDXS or RPID?

Do institutionals and insiders believe in CDXS or RPID?

Which has better earnings & valuation, CDXS or RPID?

Which has more volatility and risk, CDXS or RPID?

Is CDXS or RPID more profitable?

Summary

How does Rapid Micro Biosystems compare to MaxCyte?

Which has preferable earnings and valuation, MXCT or RPID?

Do institutionals and insiders have more ownership in MXCT or RPID?

Is MXCT or RPID more profitable?

Does the media prefer MXCT or RPID?

Which has more volatility & risk, MXCT or RPID?

Do analysts recommend MXCT or RPID?

Summary

How does Rapid Micro Biosystems compare to Quanterix?

Is RPID or QTRX more profitable?

Which has more risk & volatility, RPID or QTRX?

Does the media refer more to RPID or QTRX?

Do institutionals and insiders hold more shares of RPID or QTRX?

Do analysts recommend RPID or QTRX?

Which has better valuation and earnings, RPID or QTRX?

Summary

How does Rapid Micro Biosystems compare to Nautilus Biotechnology?

Which has more volatility and risk, NAUT or RPID?

Which has stronger earnings and valuation, NAUT or RPID?

Is NAUT or RPID more profitable?

Does the media favor NAUT or RPID?

Do insiders & institutionals believe in NAUT or RPID?

Do analysts recommend NAUT or RPID?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RPID vs. The Competition

Rapid Micro Biosystems Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools